JP2023551712A5 - - Google Patents

Info

Publication number
JP2023551712A5
JP2023551712A5 JP2023533382A JP2023533382A JP2023551712A5 JP 2023551712 A5 JP2023551712 A5 JP 2023551712A5 JP 2023533382 A JP2023533382 A JP 2023533382A JP 2023533382 A JP2023533382 A JP 2023533382A JP 2023551712 A5 JP2023551712 A5 JP 2023551712A5
Authority
JP
Japan
Prior art keywords
relative humidity
api
stable oral
weight
oral formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023533382A
Other languages
English (en)
Japanese (ja)
Other versions
JP7678106B2 (ja
JP2023551712A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2021/017842 external-priority patent/WO2022119269A1/ko
Publication of JP2023551712A publication Critical patent/JP2023551712A/ja
Publication of JP2023551712A5 publication Critical patent/JP2023551712A5/ja
Application granted granted Critical
Publication of JP7678106B2 publication Critical patent/JP7678106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023533382A 2020-12-01 2021-11-30 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸を含む安定した経口用製剤 Active JP7678106B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200166051 2020-12-01
KR10-2020-0166051 2020-12-01
PCT/KR2021/017842 WO2022119269A1 (ko) 2020-12-01 2021-11-30 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제

Publications (3)

Publication Number Publication Date
JP2023551712A JP2023551712A (ja) 2023-12-12
JP2023551712A5 true JP2023551712A5 (https=) 2025-03-21
JP7678106B2 JP7678106B2 (ja) 2025-05-15

Family

ID=81854222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533382A Active JP7678106B2 (ja) 2020-12-01 2021-11-30 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸を含む安定した経口用製剤

Country Status (15)

Country Link
US (1) US20240000751A1 (https=)
EP (1) EP4257123A4 (https=)
JP (1) JP7678106B2 (https=)
KR (1) KR20220077091A (https=)
CN (1) CN116528852A (https=)
AR (1) AR124178A1 (https=)
AU (2) AU2021390901B9 (https=)
CA (1) CA3197405A1 (https=)
CL (1) CL2023001215A1 (https=)
CO (1) CO2023008265A2 (https=)
MX (1) MX2023005459A (https=)
PE (1) PE20240222A1 (https=)
TW (3) TWI896975B (https=)
WO (1) WO2022119269A1 (https=)
ZA (1) ZA202305156B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240242A1 (es) * 2021-06-15 2024-02-16 Lg Chemical Ltd Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000862A (es) * 2002-07-31 2005-04-19 Pharmacia Corp Forma de dosificacion farmaceutica capaz de mantener un perfil de disolucion estable tras el almacenamiento.
DE602006014607D1 (de) * 2005-01-21 2010-07-15 Teva Pharma Stabile pharmazeutische Zusammensetzungen von Zonisamide und Verfahren zur deren Herstellung
JP5330989B2 (ja) * 2007-04-11 2013-10-30 キッセイ薬品工業株式会社 (アザ)インドール誘導体及びその医薬用途
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI548630B (zh) * 2011-04-06 2016-09-11 Lg生命科學有限公司 1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸結晶型及其製造方法
WO2020109319A1 (en) * 2018-11-27 2020-06-04 Zaklady Farmaceutyczne Polpharma S.A Pharmaceutical composition comprising ramipril and indapamide
US20240000750A1 (en) * 2020-11-04 2024-01-04 Lg Chem, Ltd. Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same
PE20230850A1 (es) * 2020-12-01 2023-05-23 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
TWI903066B (zh) * 2021-04-16 2025-11-01 南韓商Lg化學股份有限公司 包含1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸之口服用複合調配物

Similar Documents

Publication Publication Date Title
JP2021512117A5 (https=)
IL275982B2 (en) Pharmaceutical compositions for treating cystic fibrosis
US6340695B1 (en) Rapid onset formulation
CA2483199A1 (en) High drug load tablet of imatinib
JP2023551712A5 (https=)
JP2020517732A5 (https=)
US20130344150A1 (en) Direct compression tablets of otilonium
US20160184268A1 (en) Compositions of eltrombopag
JP2020511419A5 (https=)
JP2007503414A5 (https=)
JP2019523258A (ja) エソメプラゾール、又は薬学的に許容可能なその塩を含むpH依存性薬物放出特性が改善した剤形
JP2022044699A5 (https=)
JP2016530238A5 (https=)
JP2023536667A5 (https=)
JP2021512869A5 (https=)
JP2023544327A5 (https=)
JP2023532223A5 (https=)
JP2018530566A5 (https=)
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
JP2023548855A5 (https=)
US20240000751A1 (en) Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
JP7226697B2 (ja) ブロナンセリン含有錠剤
JP2024525954A5 (https=)
US10966971B2 (en) Pharmaceutical compositions of pomalidomide
JP2025535941A5 (https=)